| Literature DB >> 36233434 |
Nischal Koirala1,2, Jyotsna Joshi1, Stephen F Duffy3, Gordon McLennan2.
Abstract
Percutaneous-reinforced osteoplasty is currently being investigated as a possible therapeutic procedure for fracture stabilization in high-risk patients, primarily in patients with bone metastases or osteoporosis. For these patients, a percutaneous approach, if structurally sound, can provide a viable method for treating bone fractures without the physiologic stress of anesthesia and open surgery. However, the low strength of fixation is a common limitation that requires further refinement in scaffold design and selection of materials, and may potentially benefit from tissue-engineering-based regenerative approaches. Scaffolds that have tissue regenerative properties and low inflammatory response promote rapid healing at the fracture site and are ideal for percutaneous applications. On the other hand, preclinical mechanical tests of fracture-repaired specimens provide key information on restoration strength and long-term stability and enable further design optimization. This review presents an overview of percutaneous-reinforced osteoplasty, emerging treatment strategies for bone repair, and basic concepts of in vitro mechanical characterization.Entities:
Keywords: bone biomechanics; cementoplasty; mechanical testing; percutaneous osteoplasty; three-point/four-point flexural test
Year: 2022 PMID: 36233434 PMCID: PMC9571370 DOI: 10.3390/jcm11195572
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Currently available therapies for the management of bone metastases with IR.
| IR technique. | Description | Advantages and Disadvantages | Ref. |
|---|---|---|---|
| Mechanical stabilization | |||
| Cementoplasty | Use of bone cement for bone consolidation and pain palliation. | Widely available procedure at low cost. PMMA cement has low resistance to bending and twisting, toxicity, and cement leakage. | [ |
| Reinforcement cementoplasty | Use of reinforcements such as K-wires, nails, and screws in addition to regular cementoplasty. | Provides additional mechanical stability. Infection, pain, and reinforcement failures. | [ |
| Tumor destruction | |||
| Ablation—Radiofrequency (RFA) and microwave (MWA) | Tumor destruction with the application of high temperature (≥60 ° C). | RFA—Cost-effective, widely used. Suffers from local perfusion or vascular heat sink effects, less powerful than MWA, and non-homogeneous energy propagation. | [ |
| Cryoablation | Tumoricidal effects from exposure to extremely cold temperatures of super-cooled gases (<−40 °C). | Deep tissue penetration, ablated areas visible in imaging due to ice-ball formation (temperature difference), and less damage to tissue architecture. Costlier than RFA or MWA, cryoshock, and not indicated for all tumors. | |
| Embolization | Obstruction of tumor-feeding blood vessels that cuts off nutrients and oxygen supply (devascularization) choking tumor cells. | Less bleeding and rapid cut-off of blood supply. Infection, ischemia, and potential damage to healthy tissues from wrong delivery. | [ |
| MR-guided Focused Ultrasound (MRgFUS) (also called, High-Intensity Focused Ultrasound [HIFU]). | Application of focussed ultrasonic pulses to lyse tumor cells with MR-based tissue identification and targeting. | Minimally invasive and does not require tissue contact via needlelike applicators to deliver ultrasonic waves. Shallow penetration depth. | |
Figure 1Block diagram illustrating percutaneous-reinforced osteoplasty procedure. A mid-diaphyseal fracture of the tibia in a strictly “non-surgical” patient is repaired radio-surgically by creating access with a bone biopsy needle followed by insertion of reinforcement material(s) and cement augmentation.
Materials commonly used for reinforcements in percutaneous osteoplasty.
| Material | Evidence | Advantages | Disadvantages | Ref. |
|---|---|---|---|---|
| PMMA bone cement | Preclinical | Readily available, ease of use, high axial compressive strength (80–94 MPa). | Low bending (67–72 MPa), tensile (36–47 MPa; Young’s modulus: ~2400 MPa), and shear strength (50–69 MPa). | [ |
| Calcium phosphate cement | Clinical | Good osteoconductive properties, mimics natural mineral phase of bone, low toxicity. | More expensive than PMMA cement, and has low mechanical strength (compressive strength: 35 MPa). | [ |
| Stents | Preclinical | Ease of deployment in the target site. | Low mechanical strength, and displacement. | [ |
| Nails (Screws) | Preclinical | Bone consolidation, stability, and durability. | Breaking, loosening, or migration. | [ |
| K-wires | Preclinical | Ease of deployment, deployable in bundles to boost strength. | Low mechanical strength. | [ |
| Y STRUTS | Preclinical | Bone consolidation, reinforces mechanical stability. | Increase in procedural complexity and time, application limited to proximal femur. | [ |
Figure 2Percutaneous-reinforced osteoplasty procedure [12]. (a) Access to the intramedullary canal is established with a bone needle through a cortical hole adjacent to the fracture line, (b) cement injection (initial phase) via bone cannula, (c) cement injection (final phase), (d) stent and wire scaffolding in position following cementoplasty, (e) artistic representation of stent-wire-cement scaffolding strategy (percutaneous-reinforced osteoplasty). (Parts of figures were reprinted with permission, © 2020 Springer, [12]).
Summarized results of recent studies involving percutaneous osteoplasty with/without reinforcement for management of bone metastases.
| Lesion Localization (Patients (n), (Year)) | Intervention Type | Outcome | Complications | Reference |
|---|---|---|---|---|
| Hip and neck ( | Screw fixation and cementoplasty for pathologic bone fractures. | Significant decrease in pain score from 8.0 ± 2.7 to 1.6 ± 2.5, lower analgesic consumption from 70.9 ± 37 to 48.2 ± 46 mg/day, and improved EQ5D score from 42.5 ± 13.6 vs. 63.6 ± 10.3 ( | Minor subcutaneous hematoma ( | [ |
| Pelvic Ring ( | Percutaneous fixation with internal cemented screws (FICS) for prophylactic consolidation of large osteolytic tumors. |
Postprocedural VAS: 0.76 ± 1.73 (preprocedural VAS: ≤3, out of 10). Long-term consolidation efficacy—98% (follow-up period 22 months). | Self-resolving hematoma ( | [ |
| Hip, shoulder, chest, and jaw ( | Percutaneous image-guided screw fixation (PIGSF) of insufficiency, impending or pathological fractures. | Extremely low rates (<4%) of per-procedural (cement leak, induced fracture, or hematoma) and early complication (≤24 h) following PIGSF. | Delayed complications (>24 h, total: 18%) included infection (most frequent), focal pain, tumor seeding, screw loosening and fracture. | [ |
| Periarticular load-bearing bones ( | Ablation, osteoplasty, reinforcement, and internal fixation (AORIF) of osteolytic lesions of the pelvis, hip, knee, and ankle. |
Significant reduction in pain and function 2 weeks after procedure: VAS pain score decreased from 8.32 ± 1.70 to 2.36 ± 2.23, combined pain and functional ambulation score improved from 4.48 ± 2.84 to 7.28 ± 2.76, and Musculoskeletal Tumor Society score improved from 45% to 68%. No complications or infections noted from AORIF procedure during surgery or at 30 days. | None reported. | [ |
| Femoral neck ( | FICS in metastatic patients with impending pathological fracture. |
Short-term palliative efficacy: VAS score improved from 4.2 ± 3.2 to 1.8 ± 2.0 ( Long-term consolidation efficacy—92% (follow-up period >1.5 year). |
Self-resolving hematomas ( Secondary fracture (5%). | [ |
| Sternum ( | FICS for sternal fracture fixation or consolidation of osteolytic metastases. |
Reduction in pain (Numeric Pain Rating Scale (NPRS) score: from 5.6/10 ± 2.8 to 1.1/10 ± 1.6) and decrease or withdrawal of analgesic consumption at post-procedural consultation. No secondary intervention required (follow-up period >1 year). |
Hematoma ( Secondary fracture (11%). | [ |
| Pelvic bone ( | Percutaneous osteoplasty for treatment of pelvic bone metastases. |
Pain score (VAS) decreased significantly post-procedure from 6.87 ± 1.33 to 3.33 ± 1.94 (day 3), 2.26 ± 1.59 (1 month), 1.89 ± 1.53 (3 months), 1.87 ± 1.46 (6 months), 1.90 ± 1.47 (9 months), and 1.49 ± 1.17 (12 months). Oswestry Disability Scores (ODI) scores changed significantly after the procedure and at each follow-up visit (3 days, 1-, 3-, 6-, 9-, and 12 months) compared to baseline. |
Notable extraosseous cement leakage (28%) albeit without any clinical complication. No pain relief (6%) or pain aggravation (1%). | [ |
| Spine ( | Microwave ablation and cementoplasty for treatment of painful spinal metastases. |
VAS score decreased from 7.0 ± 1.8 (preprocedural) to 2 ± 1.6 (2–4 weeks) and 2 ± 2.1 (20–24 weeks) postprocedurally. ODI score decreased from 46 ± 17.9 (preprocedural) to 24 ± 17.1 (2–4 weeks) and 24 ± 18.8 (20–24 weeks) postprocedurally. | S1 nerve thermal injury ( | [ |
| Pelvic bone and lower leg ( | Extraspinal cementoplasty for bone metastasis. |
Improvement in pain score from 4.2 ± 3.6 (before cementoplasty) to 1.09 ± 2.4) (week 1) for 31 patients. Improvement in quality of life (48%) and disability (52%) at 22 months postprocedure ( | Cement leakage (12%), hematoma (2%), and acute respiratory distress due to infection (2%). | [ |
Figure 3Percutaneous augmented osteoplasty with a metallic mesh containing 25–50 medical-grade stainless steel microneedles and PMMA cement [13,21]. Upper panel: A large, solitary, lytic metastatic lesion of the humeral head in a patient with esthesioneuroblastoma treated for pain palliation with augmented osteoplasty. (a) Under fluoroscopic guidance, 25–50 stainless steel microneedles (22-ga., 2–6 cm length) were inserted through the needle’s trochar, followed by, (b) PMMA cement injection, (c) X-ray image of the implant at 3-month follow-up showed needles in the original location (no migration). (Reprinted with permission, © 2015 Elsevier, [21]). Lower panel: Similar concept was applied to patients with multiple myeloma and painful lesion of the left femoral bone. (d,e) Insertion of metallic mesh (microneedles) through bone access needle in the lesion site in multiple orientations under fluoroscopic control, followed by, (f) PMMA cement injection. (Reprinted with permission, © 2016 Springer, [13]).
Figure 4Chitosan fiber and calcium phosphate ceramics (CF/CPC) scaffold for fracture repair in weight-bearing long bones (radiuses) [61]. Upper panel: (a) X-ray images of both radii in adult dogs, right radius received CF/CPC scaffold, left radius were untreated (blank control). Radiographic images post-implantation at various time points in the experimental group: (b) 0 weeks, (c) 4 weeks, (d) 8 weeks, (e) 12 weeks. Lower panel: Histological examination of the bone-defect area tissue at 4-, 8-, and 12 weeks after surgery. The experimental group showed time-dependent slow resorption of cement and the formation of new bone tissues. In contrast, no biological activity occurred in the control group.
Figure 5Osseous integration of calcium phosphate cement versus PMMA cement by histomorphometry in a canine model (osteopenic foxhound) that received intravertebral cement implant [63]. (a,b) PMMA implant (left) showing 30% of direct bone contact versus >80% of osseous integration with calcium phosphate cement (right) (imagery at 6 months; bone contact observed as early as 3 months after implantation) (green line—direct contact, red line—no contact). (c,d) Osteonal penetration occurred in the bone-calcium phosphate interface (left) but not in the bone-PMMA interface (right) (images after 12 months). Additionally, the study reported an increase in the number of osteons with time in calcium phosphate implants (not shown). (Reprinted with permission, © 2006 Springer, [63]).
Common types of carrier materials for delivery of bone morphogenetic proteins.
| Type | Examples | Advantages | Disadvantages | Ref. |
|---|---|---|---|---|
| Natural | Collagen, Hyaluronans, fibrin, chitosan, silk | Biocompatible, Bioresorbable | Procurement, disease transmission, immunogenicity | [ |
| Synthetic | Polylactide, polyglycolide, PLGA | Design flexibility, no disease transmission | Inflammatory response, poor clearance due to high molecular weight | |
| Inorganic | Calcium orthophosphates, Bioglass | Biocompatible, Bioresorbable, osteoconductive | Low mechanical property, lack of macroporosity for cell infiltration | |
| Composite | Composite materials that include natural, synthetic, and/or inorganic components | Biocompatibility, improved handling | Phase separation |
Figure 6Flexural test setup. (a) 3-point test, (b) quarter-point loading (4-point test), (c) third-point loading (4-point test), (d) specimen potted for a 4-point test (to overcome its short gauge length). Specimens can be potted in circular or rectangular cups. p–applied load, L–gauge length (distance between supports), H–specimen vertical depth (thickness).
Mechanical parameters quantifiable from a flexural test (3-point and 4-point testing).
| Parameter | Center Point Load | 4-Point Test | Reference | |
|---|---|---|---|---|
|
|
| |||
| Flexural strength |
|
|
| [ |
| Flexural modulus |
|
|
| |
| Deflection |
|
|
| |
| Bending moment |
|
|
| |
p = applied load, L = gauge length, H = thickness (depth) of the specimen, I = area moment of inertia, δ = deformation, E = Modulus of elasticity.
Figure 7Custom-designed 4-point bend test fixture to overcome bone anisotropy [80]. The setup evaluated bone bending stiffness in 24 planes (360°) upon application of a non-destructive force (no plastic deformation). The specimen was simply supported at its end and not rigidly fixed. (1) Test specimen, (2) grooved metal cups, (3) corresponding rings, (4) lug for holding the specimen in the fixture, (5) 4-point supporting fixture (bottom), and (6) 4-point loading fixture (top). (Reprinted with permission, © 1998 Elsevier, [80]).
Figure 8In silico testing of reinforced cementoplasty of the proximal femur [94]. (a) Normal healthy bone (left) and a diseased bone (right) model that received cementoplasty plus spindles, (b) proximal femur loading (1000 N) to simulate physiological loading conditions, color-coded depiction of forces (c) within, and on the (d) surface of cervicotrochanteric region (red—high magnitude forces, blue—low magnitude forces). A fracture line was included in the diseased bone to model the femoral neck fracture (shown by black arrowhead). No significant difference in mechanical constraints was observed between the normal bone and RC-repaired bone. The simulations were executed in Solidworks software (Dassault Systèmes, France). (Reprinted with permission, © 2017 Springer, [94]).